Corpus ID: 49216385

Standardizing the Decision Process to Personalize a Therapy with a Theranostic : The Options for Test Index ( OFT i )

@inproceedings{Roth2008StandardizingTD,
  title={Standardizing the Decision Process to Personalize a Therapy with a Theranostic : The Options for Test Index ( OFT i )},
  author={M. Roth},
  year={2008}
}
  • M. Roth
  • Published 2008
  • While the top pharmaceutical companies have all made investments at an R&D stage in biomarkers and genetics to aid drug selection and clinical trials, only a few have taken targeted therapies all the way through the development pathway and onto the market. A key question for those companies who have not yet acquired this level of experience is, “What exactly are the decision processes essential to guide early commercial commitment, i.e. the commitment to market a therapy alongside a theranostic… CONTINUE READING
    1 Citations

    Figures and Tables from this paper

    References

    SHOWING 1-10 OF 10 REFERENCES
    Role of the Opportunity To Test Index in integrating diagnostics with therapeutics.
    • 2
    • PDF
    Patents and new product development in the pharmaceutical and biotechnology industries
    • 56
    • PDF
    First‐mover advantages
    • 2,372
    Ventana, http://www.pharmalot.com/ 2007/10/roches-humer-insists-he-will-win-ventana/. Ventana indeed finally capitulated to Roche in January 2008 based on a per share offer of $89.50
    • 2008
    Companion Diagnostics: Enabling Personalized Medicines in Cancer,
    • Spectrum Reports, Biomarkers and Diagnostics,
    • 2006
    Conversations on Health with Sidney Taurel, May 10, 2006.www.phrma.org/about_phrma/ceo_voices/kaiser_conversations_on_ health_with_sidney_taurel
    • 2006
    Fear of Theranostics
    • Decision Resources, November
    • 2005
    Diffusion of Innovation, 5th Edition
    • 2003